Form 4 for ELTX Elicio Therapeutics, Inc.
Accepted 2024-12-18 00:00:00 ET · period of report 2024-12-16 · accession 0001601485-24-000109 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-18 | 2024-12-16 | ELTX | DeMuth Peter | CSO | M - OptEx | $4.41 | +381 | 381 | New | +$1,680 |
| D | 2024-12-18 | 2024-12-16 | ELTX | DeMuth Peter | CSO | M - OptEx | $0.00 | -381 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-16 | M | A | 381 | $4.41 | 381 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-12-16 | M | D | 381 | $0.00 | 0 | D | $4.41 · — to 2024-12-18 | 381 Common Stock | (F1) The stock option vested and became exercisable as to (i) 25% of the options on the first anniversary of the grant date or December 18, 2015, and (ii) with the remaining shares vesting at a rate of 2.0833% at the end of each month thereafter. |